RESEARCH ARTICLE

Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets

Shauna L. French, Antonia C. Paramitha, Mitchell J. Moon, Ross A. Dickins, Justin R. Hamilton*

Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

* Justin.Hamilton@monash.edu

Abstract

Anti-platelet drugs are the mainstay of pharmacotherapy for heart attack and stroke prevention, yet improvements are continually sought. Thrombin is the most potent activator of platelets and targeting platelet thrombin receptors (protease-activated receptors; PARs) is an emerging anti-thrombotic approach. Humans express two PARs on their platelets—PAR1 and PAR4. The first PAR1 antagonist was recently approved for clinical use and PAR4 antagonists are in early clinical development. However, pre-clinical studies examining platelet PAR function are challenging because the platelets of non-primates do not accurately reflect the PAR expression profile of human platelets. Mice, for example, express Par3 and Par4. To address this limitation, we aimed to develop a genetically modified mouse that would express the same repertoire of platelet PARs as humans. Here, human PAR1 preceded by a lox-stop-lox was knocked into the mouse Par3 locus, and then expressed in a platelet-specific manner (hPAR1-KI mice). Despite correct targeting and the predicted loss of Par3 expression and function in platelets from hPAR1-KI mice, no PAR1 expression or function was detected. Specifically, PAR1 was not detected on the platelet surface nor internally by flow cytometry nor in whole cell lysates by Western blot, while a PAR1-activating peptide failed to induce platelet activation assessed by either aggregation or surface P-selectin expression. Platelets from hPAR1-KI mice did display significantly diminished responsiveness to thrombin stimulation in both assays, consistent with a Par3−/− phenotype. In contrast to the observations in hPAR1-KI mouse platelets, the PAR1 construct used here was successfully expressed in HEK293T cells. Together, these data suggest ectopic PAR1 expression is not tolerated in mouse platelets and indicate a different approach is required to develop a small animal model for the purpose of any future preclinical testing of PAR antagonists as anti-platelet drugs.
Introduction

Anti-platelet drugs are the primary therapy for heart attack and stroke prevention, yet improvements are continually sought. Thrombin is by far the most potent endogenous platelet activator, which it achieves via cell surface protease-activated receptors (PARs). Due to the importance of thrombin-induced platelet activation during thrombosis, targeting platelet thrombin receptors has received significant clinical attention, and PAR antagonists are one of the most promising of the emerging anti-thrombotic approaches [1–3]. Humans express two PARs on their platelets, PAR1 and PAR4, both of which are cleaved and activated by thrombin, and both of which are capable of inducing robust platelet activation [4, 5]. PAR1 has a higher affinity for thrombin and was therefore the target of initial drug development. The first PAR1 antagonist, vorapaxar, was recently approved by the FDA for clinical use in the USA [2]. So far, however, vorapaxar has limited clinical utility due to an increase in major bleeding events associated with its use [6, 7]. These limitations on the first PAR1 inhibitor have ignited interest in evaluating the clinical potential of PAR4 antagonists, and these agents are now in early clinical development (NCT02208882) [8].

However, a major limitation in examining platelet PAR function in detail is the absence of a small animal model that accurately reflects the PAR expression profile in human platelets: only primate platelets express the PAR1/PAR4 profile [9]. This places significant limits on preclinical research into the utility of PAR antagonists in vivo. Of the commonly-used small animals, for example, platelets from mice, rats and rabbits express PAR3 and PAR4 [10–13], while guinea-pig platelets express PAR1, PAR3 and PAR4 [14]. Par4-/- mice have been crucial for early proof-of-concept studies into the overall role of PARs in thrombosis [15–17], but are unsuitable for elucidating, for example, the relative anti-thrombotic effects of PAR1 vs PAR4 inhibition.

One way to overcome this limitation is to ‘humanize’ the platelet PAR expression profile of the mouse, essentially replacing mouse PAR3 (Par3) with human PAR1 (PAR1). Initial attempts used platelet-specific expression of a PAR1 transgene in Par3-/- mice, but were unsuccessful [18]. Possible explanations for the failure of this transgene-based approach include insufficient expression levels or unpredicted gene silencing consequences as a result of nonspecific transgene insertion [18]. We theorized that ‘knock-in’ of PAR1 into the endogenous mouse Par3 locus in a manner that would allow platelet-specific expression may overcome these earlier issues and would create a mouse that expresses PAR1 and Par4 on platelets, but without further ectopic PAR1 expression. Here, we generate and characterise such a mouse. Despite correct targeting, this genetic approach failed to yield detectable expression or function of PAR1 on mouse platelets. When taken together with earlier studies using distinct approaches, this study indicates that forced expression of PAR1 in mouse platelets will be difficult to achieve and suggests that other options will be required for reliable preclinical screening of any future PAR antagonists.

Methods and Materials

Materials

Human α-thrombin and adenosine 5′-diphosphate sodium salt (ADP) were purchased from Sigma-Aldrich (St Louis, MO, USA). PAR1-activating peptide (PAR1-AP; TFLLR-NH₂) and PAR4-activating peptide (PAR4-AP; AYPGKF-NH₂) were synthesised at Monash Institute of Pharmaceutical Sciences (Melbourne, Australia) by Assoc Professor Philip Thompson. The mouse anti-P-selectin (FITC anti-mouse CD62P) and human anti-P-selectin (PE anti-human CD62P) antibodies were purchased from BD Biosciences (San Jose, CA, USA). PE anti-CD45.2,
PE anti-CD41a (human) antibody and PE anti-CD41 antibody (mouse) were purchased from Abcam (Melbourne, Australia). The PE-anti-GPIb-tail and non-immune rabbit IgG isotype were a generous gift from Assoc Professor Robert Andrews (Monash University, Melbourne, Australia). The anti-PAR1 antibody (ATAP2), anti-PAR3 antibody (8E8), HRP-anti-actin (I-19) and HRP- anti-mouse IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

**Generation of hPAR1-KI (Pf4-Cre; Par3LSL-PAR1) mice**

All mouse studies were approved by the Alfred Medical Research and Education Precinct Animal Ethics Committee (approval number E/1465/2014/M). *Pf4-Cre; Par3LSL-PAR1* mice (hereafter referred to as hPAR1-KI mice) were generated by Ozgene (Perth, Australia). The targeting vector involved exon 2 of Par3 (*F2rl2*) flanked with a lox-stop-lox and followed by exon 2 of *PAR1* (*F2r*) (Fig 1A). Since exon 1 encodes the signal peptide and exon 2 encodes the entire mature receptor for both PAR1 and Par3 [19], Cre-mediated deletion is predicted to result in the replacement of Par3 with PAR1 and leaves the endogenous Par3 promoter intact (Fig 1A). The BAC vector comprised unaltered exon 1 of Par3, then exon 2 of Par3 followed by a stop codon and flanked by loxP sites, and followed by PAR1. The vector was injected into C57BL/6J blastocysts, chimeras were bred for germline transmission, and the targeted allele bred to homozygosity (Par3LSL-PAR1). These mice were then bred with Pf4-Cre mice to induce deletion of Par3 and permit the expression of PAR1 specifically in platelets (Pf4-Cre; Par3LSL-PAR1, hereafter referred to as hPAR1-KI mice). PCR genotyping of the targeted allele was performed using the following primers: common reverse (AGCTGAAAAATGGAGCGCTTG) with WT forward (TGGGTTCCTCATCCGTGTGG, predicted size 588bp) or mutant forward (TCCTTCACCTGTCTGGCCATC, predicted size 914bp) (Fig 1A). Deletion of Par3 was confirmed by PCR using the following primers: forward (CAGTGTTACGTGCGCGGCTT) and reverse (GCCAATCATCCTGCGGAAGA; predicted size 963bp) (Fig 1A).

**Isolation of mouse and human platelets**

All human studies were approved by the Monash University Human Research Ethics Committee (CF07/0141-2007/0025). Blood was collected after written informed consent was obtained from healthy adults (21–50 years old, of both sexes) who had not taken anti-platelet medications in the past 10 d. Mouse and human blood was drawn into syringes containing acid citrate dextrose (ACD; 1:7 v/v). Platelets were isolated by centrifugation as previously described [20].

**Megakaryocyte DNA extraction**

Bone marrow cells were aseptically flushed from the femora and tibiae of mice using a syringe and a 23-gauge needle containing Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies) supplemented with 10% foetal bovine serum (FBS), penicillin, streptomycin and glutamine. Post-harvest, thrombopoietin (0.1 μg/mL) was added to the cells, which were allowed to culture for 4 d at 37°C, 5% CO2. Cells were then collected and centrifuged at 50 g for 5 min and the pellet was re-suspended in 4 mL of PBS. The cells were layered over a two-step BSA density gradient and allowed to sediment for 45 min at room temperature. The megakaryocyte-rich population was collected and centrifuged at 50 g for 5 min, and the pellet was treated with DNA extraction buffer (Bioline) and digested at 75°C for 10 min.

**Platelet aggregation**

Platelet aggregation was measured by light transmission aggregometry in a 96-well plate format. Human and mouse washed platelets (2x10^8 platelets/mL) were added to wells of a clear, flat
Fig 1. Generation of mice expressing PAR1 in place of Par3 in a platelet-specific manner. (A) Schematic of the strategy for platelet-specific expression of human PAR1 in place of mouse Par3. Top: wild-type Par3 (wt) has two exons: exon 1 encodes the signal peptide and exon 2 encodes the complete mature receptor. Middle: In the targeted allele (Par3<sub>LSL-PAR1</sub>; fl) an insert of exon 2 of human PAR1 is placed downstream of exon 2 of Par3. Par3 exon 2 is flanked by loxP sites, allowing Cre-mediated excision. Bottom: Cre-mediated deletion of Par3 exon 2 allows expression of PAR1 exon 2, resulting in a predicted chimeric protein consisting of the Par3 signal peptide fused to the mature PAR1 receptor (hPAR1-KI). Heterozygous targeted mice, Par3<sub>LSL-PAR1</sub>/+; homozygous targeted mice, Par3<sub>LSL-PAR1</sub>/Par3<sub>LSL-PAR1</sub> (Pf4-Cre;fl/fl).

(B) PCR genotyping of tail DNA using the primers indicated (black flags): wild type forward (1F), mutant forward (2F), common reverse (3R).

(C) Cre-mediated deletion of Par3 was confirmed by PCR genotyping of individual mice using DNA from both tail (not deleted) and megakaryocytes (MK; deleted), using a forward primer spanning the loxP site (3F) and PAR1 reverse (4R). A PCR product of predicted size (988bp) was only generated using MK DNA from Pf4-Cre;fl/fl mice. Sequencing of this PCR product confirmed excision of floxed sequences (S3 Fig).

doi:10.1371/journal.pone.0165565.g001
bottom, 96-well tissue culture plate (Falcon). Platelets were stimulated with either thrombin (0.01–1 U/mL), PAR1-AP (10–100 μM), PAR4-AP (10–100 μM), or ADP (1–10 μM). The plate was analysed at 37°C in a FLUOstar OPTIMA plate reader (BMG Labtech) using a 595 nm excitation filter, for a period of 50 min (10 read cycles with 5 min double orbital shake period between each read). Ability to aggregate was calculated as $\frac{OD(\text{No Agonist}) - OD(\text{Agonist})}{OD(\text{No Agonist}) - OD(\text{blank})} \times 100$ at the time point where aggregation was at a maximum. Optical density was normalised against the blank (maximum) and unstimulated platelets (minimum) and expressed as % maximum.

**P-selectin expression**

Flow cytometry was used to detect the expression of P-selectin by activated platelets. Human and mouse platelets, prepared as outlined above, were incubated with an anti-P-selectin antibody and stimulated with thrombin (0.01–1 U/mL), PAR1-AP (10–100 μM), or PAR4-AP (30–300 μM) for 15 min at 37°C. Samples were then analysed using a FACSCalibur (Becton Dickinson) flow cytometer and FlowJo software.

**Analysis of platelet PAR1 expression**

Platelets isolated from either humans or mice (5x10^7 platelets/mL in Tyrode’s buffer) were incubated with a PE-conjugated antibody against one of PAR1 (2.5 μg/10^6 cells; ATAP2), CD45 (platelet negative control antibody of matching isotype, 2.5 μg/10^6 cells), or CD41a (platelet positive control antibody of matching isotype, 2.5 μg/10^6 cells). In some experiments, isolated platelets were permeabilized with saponin (0.1% v/v) prior to incubation with antibodies. In these experiments, a PE-conjugated antibody against the cytoplasmic tail of GPIb was included to confirm effective platelet permeabilization [21]. In all cases, samples were analysed using a FACSCalibur flow cytometer and FlowJo Software. Positive expression was measured as a rightward shift in relative fluorescent intensity compared to the isotype control.

**Western blot**

Platelet proteins were analyzed in lysates of human or mouse isolated platelets (1x10^9 platelets/mL), prepared in Laemmli’s buffer, denatured (95°C for 10 min), and run on 12% SDS-polyacrylamide gels at 170 V for 40 min. Proteins were transferred to PVDF membranes (Millipore, Lake Placid, NY, USA) at 250 mA for 2 h. Membranes were blocked with TBST (0.01 mM Tris, 50 mM NaCl, 0.01% v/v Tween-20) containing 5% skim milk powder for 30 min at room temperature, incubated with either an HRP-conjugated anti-actin antibody (1 μg/mL), anti-PAR1 antibody (1 μg/mL) or anti-PAR3 antibody (1 μg/mL) at 4°C overnight, followed by a HRP-conjugated anti-mouse IgG at room temperature for 2 h. Enhanced chemiluminescence (ECL) substrate (ThermoFisher Scientific, Waltham, MA, USA) was placed onto the membrane for 1 min before exposure (ChemiDoc Touch Imaging System, Bio-Rad, Hercules, CA, USA).

**Results**

**Generation of hPAR1-KI (Pf4-Cre; Par3^LSL-PAR1) mice**

We generated mice in which PAR1 (F2R) was knocked into the Par3 (F2lr2) locus and conditionally expressed in platelets upon Pf4-Cre-mediated excision. To this end, exon 2 of PAR1 (encoding the entire mature receptor) was inserted downstream of exon 2 of Par3 flanked by a lox-stop-lox (Fig 1A). This approach leaves the promoter and exon 1 of Par3 (encoding the signal peptide) intact and results in replacement of Par3 with PAR1 after Cre-mediated excision (Fig 1A). This is predicted to yield the Par3 signal peptide linked to the complete mature
receptor of PAR1 (Fig 1A). The stability and surface expression of the predicted fusion protein was confirmed in HEK293T cells transiently transfected with vectors expressing the same sequence as that remaining after Cre-mediated excision of the targeted allele, with the predicted Par3/PAR1 fusion protein expressed at similar levels to native PAR1 (S1 Fig). We therefore went on to generate Par3LSL-PAR1/+ mice and confirmed targeting by Southern blot (S2 Fig) and PCR genotyping (Fig 1B). Heterozygous mice were bred to homozygosity (Par3LSL-PAR1/LSL-PAR1) and crossed with Pf4-Cre mice [22], with experimental mice resulting from crosses of Pf4-Cre;Par3LSL-PAR1/LSL-PAR1 x Par3LSL-PAR1/LSL-PAR1 (Fig 1B). Cre positive offspring (Pf4-Cre;Par3LSL-PAR1/LSL-PAR1) are hereafter referred to as hPAR1-KI mice and their Cre negative littersmates (Par3LSL-PAR1/LSL-PAR1) as wild-type. Appropriate Pf4-Cre-mediated deletion in the platelet/megakaryocyte lineage was confirmed by PCR of DNA isolated from megakaryocytes versus tail biopsy (Fig 1C). We used a forward primer placed upstream of the loxP site and a reverse primer in each of Par3 and PAR1 as indicated (Fig 1A). As predicted, a band of expected size was only generated in megakaryocyte DNA from hPAR1-KI mice. Sequencing of this PCR product confirmed the predicted targeting and Cre-mediated deletion (S3 Fig).

Platelets from hPAR1-KI mice do not respond to PAR1-selective activation

Mice from these crosses were born at the expected rates, were normal in weight and appearance, and had normal whole blood counts (S1 Table). We assessed PAR1 function in platelets isolated from hPAR1-KI mice using two distinct markers of platelet activation: platelet aggregation and P-selectin expression. PAR1-selective activation by a PAR1-AP failed to aggregate platelets from hPAR1 mice at concentrations up to 100 μM (100 times the concentration required to cause platelet activation in human platelets [23]) (Fig 2A). This lack of response...
was identical in platelets from wild type mice (Fig 2B). As expected, PAR1-AP induced a robust aggregation response in human platelets (Fig 2C). A similar pattern of responses was observed when P-selectin expression was used as the marker of platelet activation, with PAR1-AP unable to elicit any response in platelets isolated from either hPAR1-KI (Fig 2D) or wild type (Fig 2E) mice, but a robust response in human isolated platelets (Fig 2F). Together, these data indicate lack of functional PAR1 in platelets from hPAR1-KI mice.

Lack of PAR1 expression on platelets from hPAR1-KI mice

We next examined PAR1 expression in platelets from hPAR1-KI mice. We were unable to detect PAR1 on the surface of platelets from hPAR1-KI mice by flow cytometry (Fig 3A). As with the functional experiments, platelets from wild type mice and humans served as effective negative and positive controls for PAR1 surface expression by this method, respectively (Fig 3B and 3C). In all experiments, the platelet specific marker, CD41, and normal forward/side scatter properties were used to confirm the integrity of the platelets being assessed (Fig 3).

We also tested for PAR1 expression in permeabilized platelets. In these experiments, an antibody against the cytoplasmic tail of GPIbα [21] was used as a positive control for successful permeabilization. As predicted, this antibody only recognised an epitope on the internal surface of the platelet membrane, with no staining of intact platelets and strong staining in permeabilized platelets from both mice and humans (S4 Fig). However, we were unable to detect any PAR1 in permeabilized platelets from hPAR1-KI mice (Fig 4A). Again, platelet integrity was confirmed by CD41 expression in all cases, while permeabilization was confirmed by

Fig 3. PAR1 is undetectable on the surface of platelets from hPAR1-KI mice. Platelets isolated from hPAR1-KI mice, wild type mice, or humans were either left unstained (black) or were incubated with a PE-conjugated antibody against one of PAR1 (blue) or CD41a (grey; positive platelet control), or an isotype control (red). (A) Platelets were gated by forward and side scatter as shown. (B-D) PAR1 was detected on human platelets but not platelets from either hPAR1-KI or wild type mice. Data shown are representative traces of n = 3 individual experiments.

doi:10.1371/journal.pone.0165565.g003
detection with the anti-GPIbα-tail antibody (Fig 4). Platelets from wild type mice and humans again served as controls (Fig 4B and 4C), indicating the anti-PAR1 antibody still binds its epitope in permeabilized cells.

Finally, we also examined PAR1 expression by Western blot. Here, a band at the predicted size of approximately 75 kD was detected in lysates of human platelets, but not of wild-type or hPAR1-KI mouse platelets (Fig 5), mirroring the flow cytometry data. Together, these findings indicate PAR1 is not expressed at detectable levels in platelets from hPAR1-KI mice.

PAR3 expression and function is disrupted in platelets from hPAR1-KI mice

Our genetic strategy is predicted to disrupt Par3 expression in platelets. This was confirmed genetically by PCR genotyping and sequencing (Fig 1). Regardless, given the lack of PAR1 expression or function in platelets from hPAR1-KI mice, we therefore also probed for Par3 protein in these platelets. We never detected Par3 expression by Western blot in human platelets, but routinely observed a band of the previously reported size (approximately 50kDa) in wild type mouse platelets (Fig 5). This band was absent in platelet lysates from all hPAR1-KI mice examined (Fig 5), further confirming disruption of Par3 in hPAR1-KI mice. To further examine this, we tested for the predicted functional effects of Par3-deficiency.

Platelets from Par3−/− mice exhibit diminished responsiveness to thrombin [24]. Here, we observed a similar effect in platelets from hPAR1-KI mice. We examined platelet aggregation and P-selectin expression in response to thrombin. Platelets from hPAR1-KI mice exhibited an approximately 3-fold decrease in sensitivity to thrombin in both assays when compared to platelets from wild type mice (Fig 6). Specifically, aggregation of hPAR1-KI platelets was only
achieved at thrombin concentrations of 0.3 U/mL and above (Fig 6A) compared with 0.1 U/mL and above for wild type platelets (Fig 6B). A similar pattern emerged when examining P-selectin expression in response to thrombin: aggregation of hPAR1-KI platelets was only achieved at thrombin concentrations of 1 U/mL (Fig 6D) compared with 0.3 U/mL and above for wild type platelets (Fig 6E).

Importantly, hPAR1-KI platelets responded normally to other agonists, PAR4-AP and ADP (Fig 7). When comparing platelets from hPAR1-KI and wild type mice, near-identical concentration-responses were observed for ADP-induced aggregation (Fig 7A and 7B), PAR4-AP-induced aggregation (Fig 7D and 7E), and PAR4-AP-induced P-selectin expression (Fig 7G and 7H). These functional data are consistent with the phenotype observed in platelets from Par3-/- mice and, when combined with the failure to detect Par3 expression in hPAR1-KI platelets, suggest correct targeting and Par3 deletion in hPAR1-KI mice.

Discussion

PARs are leading targets for new anti-platelet drugs, exemplified by the recent approval of the PAR1 antagonist, vorapaxar, and the early clinical development of the PAR4 antagonist, BMS-986120. Given the increased focus of examining PAR antagonists as anti-platelet agents, there
is much interest in developing an appropriate small animal model for in vivo testing of such drugs. This has proved to be a major limitation in the field, as the PAR1/PAR4 expression profile of human platelets is only shared amongst primates. Here, we attempted to create a genetically-modified mouse that mimics the PAR1/PAR4 expression profile of human platelets. To do this, we knocked the human PAR1 gene into the mouse Par3 locus in a manner that provided for platelet-specific replacement of Par3 with PAR1. Correct targeting was confirmed genetically and was apparent functionally. Yet despite this, we were unable to detect expression or function of PAR1 in platelets from these mice, indicating the approach used here is insufficient to ‘humanize’ platelet PAR expression in mice by inducing PAR1 expression in place of Par3.

Forced PAR1 expression has been previously achieved using transgene-based approaches in other cell types. For example, mouse PAR1 (Par1) was specifically expressed in endothelial cells via the Tie2 promoter/enhancer [25] and in cardiomyocytes via the αMHC promoter [26]. In addition, PAR1 has been expressed in mouse mammary gland epithelium [27]. In contrast to these successes, a previous attempt failed to express either Par1 or PAR1 transgenes in mouse platelets via multiple platelet-specific promoters [18]. The reasons for the inability to express PAR1 in mouse platelets remain unknown. However, given the limitations and lack of control associated with transgene-based approaches, we used a knock-in approach in which PAR1 was targeted to the Par3 locus, essentially resulting in replacement of Par3 with PAR1, and with expression governed by the endogenous mouse Par3 promoter.

Correct genetic targeting was confirmed by multiple methods, including Southern blot analysis of founders, PCR genotyping across the insert, and PCR analysis of correct Pf4-Cre-mediated excision in the DNA in isolated megakaryocytes. Correct targeting was also apparent by the absence of Par3 expression in platelets from hPAR1-KI mice. The disruption of Par3 expression was further supported by functional analyses of these platelets that revealed a

Fig 6. Platelets from hPAR1-KI mice exhibit diminished responses to thrombin. Platelets isolated from (A, D) hPAR1-KI mice, (B, E) wild type mice, or (C, F) humans were with thrombin and examined for (A-C) platelet aggregation by light transmission aggregometry or (D-F) P-selectin expression by flow cytometry. Note the approximate 3-fold decrease in sensitivity to thrombin-induced responses in platelets from hPAR1-KI mice versus wild-type mice in both assays. Data are mean ± SEM of n = 4–7 experiments.

doi:10.1371/journal.pone.0165565.g006
phenotype remarkably similar to that observed in platelets from Par3−/− mice [24], with an approximately 3-fold decrease in sensitivity to thrombin-induced platelet activation. Together, this detailed analysis indicates correct targeting occurred in these mice and resulted in disruption of Par3 expression. However, no replacement PAR1 expression or function was detected. The reason behind this lack of expression of PAR1 in mouse platelets is unknown. Our initial functional studies showed that hPAR1-KI platelets did not respond to a PAR1-specific agonist but responded normally to other agonists, suggesting that the receptor was either absent or unable to signal. We probed extensively for protein expression but were unable to detect PAR1 in platelets from hPAR1-KI mice via flow cytometry or Western blot. The lack of detection of PAR1 even in permeabilized platelets (by flow cytometry) or in whole cell platelet lysates (by Western blot) strongly suggest that the PAR1 protein is either not translated or is very rapidly degraded. The inability of mouse platelets to ectopically express PAR1 so far appears unique, but remains unexplained and could arise from a number of critical stages in the development of mature PAR1 protein. While possible that the Par3 signal peptide is insufficient to guide PAR1 to the cell surface [28], the highly conserved nature of signal peptides coupled with our observation of robust surface expression of the fusion protein in HEK293T cells suggest otherwise. Other potential explanations include as yet unidentified mechanisms that appear unique to the mouse platelet, such as poor or defective N-linked glycosylation of the receptor leading to receptor instability and signaling dysfunction [29, 30]. Since the primary aim of this study

Fig 7. Platelets from hPAR1-KI mice respond normally to PAR1-independent platelet agonists. Platelets isolated from (A,D,G) hPAR1-KI mice, (B,E,H) wild type mice, or (C,F,I) humans were stimulated with either (A-C) ADP or (D-I) a PAR4-activating peptide (PAR4-AP) and assessed by (A-F) platelet aggregation or (G-I) P-selectin expression. Note the near-identical concentration-dependent responses in platelets from hPAR1-KI and wild type mice in all cases examined. Data are mean ± SEM of n = 3 experiments. doi:10.1371/journal.pone.0165565.g007

Mouse Platelets Do Not Tolerate PAR1 Expression

PLOS ONE | DOI:10.1371/journal.pone.0165565.October 27, 2016 11 / 14
was to generate a research tool for *in vivo* thrombosis studies, we did not explore the precise mechanism behind the lack of tolerance for PAR1 expression in mouse platelets. Whether or not replacement of the entire human *PAR1* gene in the mouse Par3 locus will be sufficient to drive expression in mouse platelets remains unknown. Regardless, it appears that other approaches will need to be examined if a non-primate model is to be used for pharmacological screening of drugs targeting platelet PARs.

### Supporting Information

**S1 Fig.** The receptor generated in hPAR1-KI mice can be expressed in HEK293T cells. The fusion protein predicted to be expressed by hPAR1-KI mice, consisting of the mPAR3 signal peptide attached to the mature hPAR1 receptor, can be expressed on the surface of transfected HEK293T cells. HEK293T cells were transfected with native hPAR1 (purple), the mPAR3/hPAR1 fusion (pink), or empty vector (yellow). Note the similar level of detectable expression of native hPAR1 and the mPAR3/hPAR1 fusion. Also shown is a positive control for surface expression (Thy-1) in cells transfected with the empty vector. (TIFF)

**S2 Fig.** Southern blot analyses of targeted ES cells and founder mice. (A) ES cell clones were screened for targeting by Southern blot. Targeted clones are indicated by the expected additional band at 8.3kb (e.g. clones D1 and D4). (B) Founder mice screened by the same Southern blot approach as in (A), showing results for 13 mice from two litters. Seven of the 13 mice genotyped as heterozygous targeted, exhibiting both the wt (11.6 kb) and mutant band (8.3kb). (TIFF)

**S3 Fig.** Sequence annotation for the hPAR1-KI allele. (A) Predicted genomic DNA sequence for the hPAR1-KI allele, showing *Par3* exon 1 highlighted in grey, the position of primers 3F and 4R in red, the loxP site in yellow, and *PAR1* exon 2 in blue. Red text indicates the sequence output of the PCR product from primers 3F and 4R, which was identical to the predicted genomic DNA sequence. (B) Annotated sequence of the predicted coding sequence and protein chimera, comprising the Par3 signal peptide (grey text) and PAR1 mature receptor (blue text). Red text indicates sequenced PCR product amplified from genomic DNA of hPAR1-KI mice, aligning to the predicted region of PAR1 coding sequence. (TIFF)

**S4 Fig.** Confirmation of platelet permeabilization. Platelets isolated from a mouse (left) or human (right) were either left intact (top) or were permeabilized with saponin (0.1%; bottom) prior to incubation with an antibody against the intracellular C-terminal of GPIbα (grey) or isotype control (red). The GPIbα tail antibody produced a rightward shift over isotype only in permeabilized platelets of both species, confirming successful permeabilization. Data shown are representative traces of *n* = 3 individual experiments. (TIFF)

**S1 Table.** Whole blood cell counts from wild type and hPAR1-KI mice. (DOCX)

### Acknowledgments

The authors wish to thank AMREP AS staff for animal care and members of the AMREP flow cytometry core facility for technical assistance and advice. The authors also thank Assoc Professors Philip Thompson, Elizabeth Gardiner and Robert Andrews for generously providing key reagents, and L. R. B. Cooper for valuable contributions. This work was supported by
grants to JRH from the National Health & Medical Research Council of Australia. JRH is a Future Fellow of the Australian Research Council.

**Author Contributions**

**Conceptualization:** SLF RAD JRH.

**Formal analysis:** SLF ACP MJM.

**Funding acquisition:** JRH.

**Investigation:** SLF ACP MJM RAD JRH.

**Methodology:** SLF ACP MJM RAD JRH.

**Project administration:** JRH.

**Resources:** RAD JRH.

**Supervision:** RAD JRH.

**Validation:** SLF ACP MJM.

**Visualization:** SLF.

**Writing – original draft:** SLF JRH.

**Writing – review & editing:** SLF ACP MJM RAD JRH.

**References**

1. Coughlin SR. Thrombin signalling and protease-activated receptors. *Nature*. 2000; 407:258–64. doi: 10.1038/35025229 PMID: 11001069

2. French SL, Arthur JF, Tran HA, Hamilton JR. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. *Blood reviews*. 2015; 29:179–89. doi: 10.1016/j.bmed.2014.10.006 PMID: 25467961

3. Holinstat M, Bray PF. Protease receptor antagonism to target blood platelet therapies. *Clinical pharmacology and therapeutics*. 2016; 98:72–81. doi: 10.1002/cpt.282 PMID: 26501993

4. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell*. 1991; 64:1057–68. PMID: 1672265

5. Kahn ML, Zheng Y-W, Huang W, Bigornia V, Zeng D, Moff S, et al. A dual thrombin receptor system for platelet activation. *Nature*. 1998; 394:690–4. doi: 10.1038/29325 PMID: 9716134

6. Morrow DA, Braunwald E, Bonacini MP, Amersi SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherosclerotic events. *New England Journal of Medicine*. 2012; 366:1404–13. doi: 10.1056/NEJMoa1200933 PMID: 22443427

7. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. *New England Journal of Medicine*. 2012; 366:20–33. doi: 10.1056/NEJMoia109719 PMID: 22077816

8. Ismat FA, Ma X, Wang Z, Frost CE, Ni YG, Yang J. Abstract TMP91: Phase I Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Protease-activated Receptor-4 Antagonist BMS-986120. *Stroke*. 2016; 47:ATMP91–ATMP.

9. Derian CK, Damiano BP, Addo MF, Darrow AL, D’Andrea MR, Nedelman M, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. *Journal of Pharmacology and Experimental Therapeutics*. 2003; 304:855–61. doi: 10.1124/jpet.102.042663 PMID: 12538843

10. Connolly AJ, Ishihara H, Kahn ML, Faresse RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. *Nature*. 1996; 381:516–9. doi: 10.1038/381516a0 PMID: 8632823

11. Connolly T, Condra C, Feng D, Cook J, Stranieri M, Reilly C, et al. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. *Thrombosis and Haemostasis*. 1994; 72:627–33. PMID: 7878643
12. Nakashishi-Matsui M, Zheng YY, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. *Nature*. 2000; 404:609–13. doi: 10.1038/3507085 PMID: 10766244

13. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Selleck FW. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. *The Annals of thoracic surgery*. 2005; 79:1545–50. doi: 10.1016/j.athoracsur.2004.11.006 PMID: 15854931

14. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang H-C, Addo MF, Cheung W-M, et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. *Journal of Pharmacology and Experimental Therapeutics*. 2001; 293:34–42. PMID: 11408522

15. Hamilton J, Cornelissen I, Coughlin S. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. *Journal of Thrombosis and Haemostasis*. 2004; 2:1429–35. doi: 10.1111/j.1538-7836.2004.00783.x PMID: 15304051

16. Lee H, Sturgeon S, Mountford J, Jackson S, Hamilton J. Safety and efficacy of targeting platelet protease-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. *British Journal of Pharmacology*. 2012; 166:2188–97. doi: 10.1111/j.1476-5381.2012.01944.x PMID: 22428607

17. Vandendriess ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. PAR4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:286–92. doi: 10.1073/pnas.0610188104 PMID: 17190826

18. Aracheche A, de la Fuente M, Nieman MT. Platelet Specific Promoters Are Insufficient to Express Protease Activated Receptor 1 (PAR1) Transgene in Mouse Platelets. *PloS one*. 2014; 9:e97724. doi: 10.1371/journal.pone.0097724 PMID: 24830314

19. Kahn ML, Hammes SR, Botka C, Coughlin SR. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. *Journal of Biological Chemistry*. 1998; 273:23290–6. PMID: 9722561

20. Mountford JK, Petitjean C, Putra HW, McCafferty JA, Setiabakti NM, Lee H, et al. The class II PI 3-kinase, PI3KC2alpha, links platelet internal membrane structure to shear-dependent adhesive function. *Nature Communications*. 2015; 6:6535. doi: 10.1038/ncomms7535 PMID: 25779105

21. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPlb-IX-V by ADAM family metalloproteinases. *Journal of Thrombosis and Haemostasis*. 2007; 5:1530–7. doi: 10.1111/j.1538-7836.2007.02590.x PMID: 17445093

22. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Ph4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. *Blood*. 2007; 109:1503–6. doi: 10.1182/blood-2006-04-020362 PMID: 17032923

23. Lee H, Hamilton JR. The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs. *Thrombosis and Haemostasis*. 2013; 109:164. doi: 10.1160/TH12-06-0389 PMID: 23093354

24. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. *Blood*. 2002; 100:3240–4. doi: 10.1182/blood-2002-05-1470 PMID: 12384423

25. Griffin CT, Srinivasan Y, Zheng YY, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. *Science*. 2001; 293:1666–70. doi: 10.1126/science.1061258 PMID: 11539492

26. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. *Circulation*. 2007; 116:2298–306. doi: 10.1161/CIRCULATIONAHA.107.692764 PMID: 17967980

27. Yin YJ, Katz V, Salah Z, Mazo M, Cohen I, Uziely B, et al. Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization. *Cancer Research*. 2006; 66:5224–33. doi: 10.1158/0008-5472.CAN-05-4234 PMID: 16707447

28. Zampatis DE, Rutz C, Furkert J, Schmidt A, Wustenhagen D, Kubick S, et al. The protease-activated receptor 1 possesses a functional and cleavable signal peptide which is necessary for receptor expression. *FEBS letters*. 2012; 586:2351–9. doi: 10.1016/j.febslet.2012.05.042 PMID: 22659187

29. Soto AG, Trejo J. N-linked glycosylation of protease-activated receptor-1 second extracellular loop: a critical determinant for ligand-induced receptor activation and internalization. *The Journal of Biological Chemistry*. 2010; 285:18781–93. doi: 10.1074/jbc.M110.111088 PMID: 20368337

30. Tordai A, Brass LF, Gelfand EW. Tunicamycin inhibits the expression of functional thrombin receptors on human T-lymphoblastoid cells. *Biochemical and Biophysical Research Communications*. 1995; 206:857–62. doi: 10.1006/bbrc.1995.1122 PMID: 7832797